Cold Spring Harbor team finds off-target activity can drive antitumor effects

A discovery that 10 drug candidates don't act through their reported target to kill cancer cells suggests companies revise how they validate targets.

Drug developers may need to revise how they validate drug targets, according to a Cold Spring Harbor Laboratory study that found 10 clinical oncology candidates killed tumor cells by hitting unintended targets.

The study also revealed a new target that could be inhibited to treat cancer.

Researchers

Read the full 454 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE